For the primary endpoint, Eczema Area and Severity Index (EASI) improved by 53-61% in a dose-dependent manner across the ...

SAN DIEGO and SUZHOU, China and SPRING HOUSE, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) ...

In a recent study published in Immunology, researchers investigated populations of regulatory T cells (Treg), a type of white blood cell, in various tissues. Study: The tissue-resident regulatory T ...

Nektar Therapeutics develops novel immunomodulatory drugs targeting autoimmune diseases and oncology. Click here to read why ...

Results from pre-clinical studies demonstrate immunomodulatory activity of QEL-005 across multiple immune cell lineages involved in complex autoimmune inflammation, including B cells, T cells and ...

Phase 2 data presented at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting show deep and durable tumor regressions in heavily pre-treated melanoma patients, with a mild safety ...

The immune system faces a delicate balancing act: it must be aggressive enough to fight infections and cancer, yet restrained ...

Scientists are trying a revolutionary new approach to treat rheumatoid arthritis, multiple sclerosis, lupus and other ...

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell ...

COYA 303 is an investigational biologic combination of COYA 301, Coya’s low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist (GLP-1RA), designed to deliver a multi-targeted immunomodulatory ...